Blbk Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 29-07-2024
- Paid Up Capital ₹ 1.92 M
as on 29-07-2024
- Company Age 23 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.57 M
as on 29-07-2024
- Satisfied Charges ₹ 1.96 Cr
as on 29-07-2024
- Revenue -3.48%
(FY 2023)
- Profit 42.03%
(FY 2023)
- Ebitda 5.02%
(FY 2023)
- Net Worth 61699.33%
(FY 2023)
- Total Assets 11.83%
(FY 2023)
About Blbk Pharmaceuticals
The Corporate was formerly known as Nitika Ayurvedics Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.92 M.
The company currently has active open charges totaling ₹6.57 M. The company has closed loans amounting to ₹1.96 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shelandra Kumar and Atul Singh serve as directors at the Company.
- CIN/LLPIN
U74899DL2001PTC109844
- Company No.
109844
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Blbk Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shelandra Kumar  | Director | 30-Dec-2017 | Current |
| Atul Singh | Director | 24-Feb-2020 | Current |
Financial Performance of Blbk Pharmaceuticals.
Blbk Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.48% decrease. The company also saw a substantial improvement in profitability, with a 42.03% increase in profit. The company's net worth Soared by an impressive increase of 61699.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blbk Pharmaceuticals?
In 2023, Blbk Pharmaceuticals had a promoter holding of 22.40% and a public holding of 77.60%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 24 Mar 2022 | ₹0.57 M | Open |
Uco Bank Creation Date: 26 Jun 2020 | ₹6.00 M | Open |
State Bank Of India Creation Date: 25 May 2006 | ₹0.72 M | Satisfied |
How Many Employees Work at Blbk Pharmaceuticals?
Unlock and access historical data on people associated with Blbk Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Blbk Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Blbk Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
